Assessing Agilon Health: Insights From 10 Financial Analysts

Loading...
Loading...

In the latest quarter, 10 analysts provided ratings for Agilon Health AGL, showcasing a mix of bullish and bearish perspectives.

In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.

Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish
Total Ratings 4 3 3 0 0
Last 30D 0 0 0 0 0
1M Ago 0 0 2 0 0
2M Ago 3 2 1 0 0
3M Ago 1 1 0 0 0

Analysts have recently evaluated Agilon Health and provided 12-month price targets. The average target is $18.3, accompanied by a high estimate of $28.00 and a low estimate of $9.00. Experiencing a 26.06% decline, the current average is now lower than the previous average price target of $24.75.

Understanding Analyst Ratings: A Comprehensive Breakdown

In examining recent analyst actions, we gain insights into how financial experts perceive Agilon Health. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.

Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target
Jailendra Singh Truist Securities Lowers Hold $10.00 $23.00
Lisa Gill JP Morgan Lowers Neutral $9.00 $17.00
Constantine Davides JMP Securities Announces Market Outperform $18.00 -
George Hill Deutsche Bank Lowers Hold $12.00 $27.00
Bill Sutherland Benchmark Lowers Buy $22.00 $28.00
Stephen Baxter Wells Fargo Lowers Overweight $16.00 $23.00
Jailendra Singh Truist Securities Lowers Buy $23.00 $27.00
Jamie Perse Goldman Sachs Lowers Buy $22.00 $25.00
Sean Dodge RBC Capital Lowers Outperform $23.00 $28.00
Bill Sutherland Benchmark Announces Buy $28.00 -

Key Insights:

Loading...
Loading...
  • Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Agilon Health. This insight gives a snapshot of analysts' perspectives on the current state of the company.
  • Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Agilon Health compared to the broader market.
  • Price Targets: Understanding forecasts, analysts offer estimates for Agilon Health's future value. Examining the current and prior targets provides insight into analysts' changing expectations.

Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Agilon Health's market position. Stay informed and make well-informed decisions with our Ratings Table.

Stay up to date on Agilon Health analyst ratings.

Get to Know Agilon Health Better

Agilon Health Inc is transforming healthcare by empowering community-based physicians with the resources and expertise they need to innovate the payment and delivery of care for seniors. The company enables physicians to create their own Medicare-centric globally capitated line of business.

Financial Milestones: Agilon Health's Journey

Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.

Revenue Growth: Agilon Health's remarkable performance in 3 months is evident. As of 30 September, 2023, the company achieved an impressive revenue growth rate of 74.95%. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.

Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of -2.59%, the company may need to address challenges in effective cost control.

Return on Equity (ROE): Agilon Health's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -3.59%, the company may face hurdles in achieving optimal financial performance.

Return on Assets (ROA): Agilon Health's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -1.36%, the company may face hurdles in achieving optimal financial returns.

Debt Management: Agilon Health's debt-to-equity ratio is below the industry average. With a ratio of 0.06, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.

The Core of Analyst Ratings: What Every Investor Should Know

Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.

Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Loading...
Loading...
Market News and Data brought to you by Benzinga APIs
date
▲▼
ticker
▲▼
name
▲▼
Price Target
▲▼
Upside/Downside
▲▼
Recommendation
▲▼
Firm
▲▼
Posted In: Analyst RatingsBZI-AAR
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...